Clinical Trial Detail

NCT ID NCT03270176
Title A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Debiopharm International SA
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

Avelumab + Debio 1143

Age Groups: senior adult

Additional content available in CKB BOOST